surmount-1 tirzepatide non-diabetic obesity weight loss Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials

Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial

23.89

★★★★☆4.8 (126)

Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky

24.27

★★★★★4.9 (98)

In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://ja.ma/4qaMLfO

23.46

★★★★★5.0 (157)

A 72-week trial compared the two leading GLP-1 medications in adults with obesity (no diabetes). The results: ✓ Tirzepatide: 20.2% weight loss ✓ Semaglutide: 13.7% weight loss But weight loss isn't the

28.78

★★★★★4.7 (84)

Tirzepatide is redefining obesity & diabetes care. Dual GIP/GLP-1 action → deeper weight loss, stronger metabolic control, and emerging benefits from OSA to cardiometabolic risk. The era of multi-pathway incretin therapy has

26.14

★★★★★4.9 (203)

Thinking about stopping a GLP-1 medication?, Worried about weight regain?, Here’s what the SURMOUNT trial actually found…”, The SURMOUNT-4 trial looked at what happened when people stopped tirzepatide

27.94

★★★★★5.0 (176)

Shifts in body mass index category with tirzepatide and associated changes in cardiometabolic risk factors in people with obesity: a post hoc analysis from the SURMOUNT-1 and SURMOUNT-4 trials

20.62

★★★★★4.8 (132)